PEGYLATED PROTEINS MARKET ANALYSIS

PEGylated Proteins Market, by Type (Consumables and Services), by Protein (Colony-stimulating factor, Interferons, Erythropoietin, Recombinant factor VII and Other), by Application (Cancer, Autoimmune Disease, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorder and Others), by End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations and Academic Research Institutes), and by (Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Nov 2022
Code : CMI5354
Pages :196
Formats :
Excel and PDF
Industry : Biotechnology

Market Challenges And Opportunities

Global PEGylated Proteins Market- Drivers

Increasing product launch and approvals by regulatory authorities to key players in market are expected to drive market growth over the forecast period. For instance, in November 2021, PharmaEssentia Corporation, a global biopharmaceutical innovator based in Taiwan, announced that the U.S. Food and Drug Administration (FDA) had approved BESREMi (ropeginterferon alfa-2b-njft) for the treatment of adults with polycythemia vera (PV). BESREMi is an innovative monopegylated, long-acting interferon, which exhibits its cellular effects in polycythemia vera in the bone marrow.

High prevalence of chronic diseases such as cancer, autoimmune disease, hepatitis, and others is expected to drive market growth over the forecast period. For instance, according to the data published in WCRF International, a not-for-profit association related to cancer prevention research on diet, weight, and physical activity, 18,094,716 million cases of cancer were diagnosed in 2020 globally.

Global PEGylated Proteins Market: Restraint

The major factors that hinder growth of the global PEGylated proteins market include drawbacks associated with PEGylated therapeutic proteins and high costs associated with drug development. For instance, polyethylene glycol (PEG) itself shows potential risks such as immunogenicity of PEG and PEG-containing vacuoles in cells observed with PEGylated biologicals.